MediWound

(NASDAQ) MDWD

Current Price$14.66

Market Cap$187.68M

Since IPO (2014)-88%

5 Year-55%

1 Year-27%

1 Month+3%

MediWound last closing stock price
Metric	Price	Date
Last close	USD 14.61	2026-07-17

MediWound stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+2.24%	USD 14.29	2026-07-10
1 month	+2.89%	USD 14.20	2026-06-17
3 month	-17.55%	USD 17.72	2026-04-17
Year to date	-20.86%	USD 18.46	2025-12-31
1 year	-27.13%	USD 20.05	2025-07-17
3 year	+44.2%	USD 10.13	2023-07-18
5 year	-54.92%	USD 32.41	2021-07-16
Since inception	-87.91%	USD 120.89	2014-03-20

MediWound Financials at a Glance

Market Cap

$187.68M

Revenue (TTM)

$14.48M

Net Income (TTM)

-$26.11M

EPS (TTM)

-$2.26

P/E Ratio

-6.47

Dividend

$0.00

Beta (Volatility)

0.74 (Low)

Dividend

$0.00

Beta (Volatility)

0.74 (Low)

Price

$14.66

Volume

13,536.528

Open

$14.53

Price

$14.66

Volume

13,536.528

Open

$14.53

Previous Close

$14.61

Daily Range

$14.49 - $14.72

52-Week Range

$13.54 - $21.11

Estimated Earnings Date

Aug 13, 2026

Dividend

$0.00

Beta (Volatility)

0.74 (Low)

Price

$14.66

Volume

13,536.528

Open

$14.53

Previous Close

$14.61

Daily Range

$14.49 - $14.72

52-Week Range

$13.54 - $21.11

Estimated Earnings Date

Aug 13, 2026

MDWD News

MediWound Revenue Jumps 43% in Q2

Motley Fool Markets TeamAug 14, 2025

Wednesday’s Top Health Care Stories: Pfizer, AstraZeneca, MediWound, and Gilead Sciences

Leo SunMay 21, 2014

MDWD: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About MediWound

MediWound Ltd. is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative solutions for tissue repair and regeneration. The company operates internationally, providing advanced treatments for chronic wounds and burns, with a strong emphasis on research and development.

Products and Services

NexoBrid: A biopharmaceutical product for removing eschar in burn patients
EscharEx: A bromelain-based therapy for chronic and hard-to-heal wounds
MW005: A biological product candidate for treating non-melanoma skin cancers

Growth Outlook

Recent quarterly revenue of $1.475 million shows potential for recovery
Strong cash position with $44.6 million in cash and equivalents
Ongoing R&D investments indicate commitment to product pipeline expansion

Financial Highlights

Trailing twelve months (TTM) revenue of $18.67 million reflects growth potential
Current ratio of 2.41 suggests strong liquidity position
Net income for Q1 2026 was -$2.95 million, indicating ongoing investment in growth

AI Generated • Jun 28, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

121

CEO

Ofer Gonen

Website

www.mediwound.com

Headquarters

Yavne, HM 8122745, IL

MDWD Financials

Key Financial Metrics (TTM)

Gross Margin

19.61%

Operating Margin

-193.62%

Net Income Margin

-180.30%

Return on Equity

-67.22%

Return on Capital

-48.82%

Return on Assets

-32.64%

Earnings Yield

-15.46%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$187.68M

Shares Outstanding

12.85M

Volume

13.54K

Avg. Volume

86.64K

Financials (TTM)

Gross Profit

$2.84M

Operating Income

-$28.03M

EBITDA

-$14.84M

Operating Cash Flow

-$18.77M

Capital Expenditure

-$6.37M

Free Cash Flow

-$25.13M

Cash & ST Invst.

$44.65M

Total Debt

$8.13M

MediWound Performance Analysis

MediWound annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 26,496,000	11.5%
2023	2023-12-31	USD 18,686,000	-29.5%
2024	2024-12-31	USD 20,222,000	8.2%
2025	2025-12-31	USD 16,959,000	-16.1%

MediWound sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	44.3%
Q3	2025-09-30	-4.9%
Q4	2025-12-31	-65.6%
Q1	2026-03-31	-21.0%

MediWound annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -3.93	12.9%
2023	2023-12-31	USD -0.75	-81.0%
2024	2024-12-31	USD -3.03	307.3%
2025	2025-12-31	USD -2.10	-30.8%

MediWound sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-1730.4%
Q3	2025-09-30	80.5%
Q4	2025-12-31	-133.3%
Q1	2026-03-31	58.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$1.48M

-62.7%

Gross Profit

$323.00K

-56.2%

Gross Margin

21.90%

N/A

Market Cap

$187.68M

N/A

Market Cap/Employee

$1.55M

N/A

Employees

121

N/A

Net Income

-$2.95M

-306.6%

EBITDA

-$2.59M

-613.8%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$44.65M

+16.7%

Total Debt

$8.13M

+26.5%

Accounts Receivable

$2.75M

-46.9%

Inventory

$4.77M

+33.3%

Long Term Debt

$8.13M

+26.5%

Short Term Debt

$929.00K

N/A

Return on Assets

-32.64%

N/A

Return on Invested Capital

-48.06%

N/A

Free Cash Flow

-$8.57M

-69.1%

Operating Cash Flow

-$6.75M

-64.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

IVVDInvivyd, Inc.

IVVDInvivyd, Inc.$0.69-6.44%

EPRXEupraxia Pharmaceuticals Inc.

EPRXEupraxia Pharmaceuticals Inc.$6.38-3.26%

TARAProtara Therapeutics, Inc.

TARAProtara Therapeutics, Inc.$4.09-0.37%

OBIOOrchestra BioMed Holdings, Inc.

OBIOOrchestra BioMed Holdings, Inc.$3.71+0.68%

IVAInventiva S.A.

IVAInventiva S.A.$4.50-2.60%

RNACCartesian Therapeutics, Inc.

RNACCartesian Therapeutics, Inc.$8.30+0.48%

AARDAardvark Therapeutics, Inc. Common Stock

AARDAardvark Therapeutics, Inc. Common Stock$5.73-2.22%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$98.61+0.04%

HLHecla Mining

HLHecla Mining$14.38+0.00%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$10.94-0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$68.98+0.02%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$41.92-0.02%

ADVBAdvanced Biomed

ADVBAdvanced Biomed$7.48+0.49%

TET1 Energy Inc.

TET1 Energy Inc.$6.01+0.03%

Questions About MDWD

What is the current price of MediWound?

MediWound is trading at $14.71 per share.

What is the 52-week range for MediWound?

Over the past 52 weeks, MediWound has traded between $13.54 and $21.11.

How much debt does MediWound have?

As of the most recent reporting period, MediWound reported total debt of $9.06M.

How much cash does MediWound have on hand?

MediWound reported $44.65M in cash and cash equivalents in its most recent financial results.

What is MediWound’s dividend yield?

MediWound does not currently have a dividend yield.

MediWound

MediWound Financials at a Glance

MDWD News

MediWound Revenue Jumps 43% in Q2

Wednesday’s Top Health Care Stories: Pfizer, AstraZeneca, MediWound, and Gilead Sciences

MDWD: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About MediWound

MDWD Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

MediWound Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MDWD

What is the current price of MediWound?

What is the 52-week range for MediWound?

How much debt does MediWound have?

How much cash does MediWound have on hand?

What is MediWound’s dividend yield?

Premium Investing Services